Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.72 |
| ▸ | HTR1A | P08908 | 2/20 | 0.72 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11622313 | 1.00 | LMNA (0.72) | LMNAMEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL11624508 | 0.91 | LMNA (0.58) | LMNAMEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL11624504 | 0.91 | LMNA (0.58) | LMNAMEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL11624002 | 0.89 | LMNA (0.60) | LMNAMEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL11624003 | 0.89 | LMNA (0.60) | LMNAMEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL11622674 | 0.89 | LMNA (0.57) | LMNAMEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL11622677 | 0.89 | LMNA (0.57) | LMNAMEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL11623125 | 0.88 | LMNA (0.59) | LMNAMEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL11623127 | 0.88 | LMNA (0.59) | LMNAMEN1KMT2AMAPTCYP2D6 | |
| SCHEMBL11623915 | 0.88 | LMNA (0.57) | LMNAMEN1KMT2AMAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-4125612-A | N-1-(p-Biphenylalkyl)piperazines and their use as anti-inflammatory agents | SCHERING CORPORATION (US) | 1978-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | LMNA 3207/4885MEN1 4777/4885KMT2A 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.